Abstract LB147: Updates on clinical safety and efficacy result of GC027, the first-in-human, “Off-the-Shelf” CD7 CAR-T stand-alone therapy for adult patients with relapsed/refractory T-cell lymphoblastic leukemia (r/r T-ALL)
Shiqi Li, Xi Zhang(Army Medical University), Martina Sersch(Innovacell Biotechnologie (Austria)), Zhongtao Yuan, Zhimin Li(Innovacell Biotechnologie (Austria)), Ruihao Huang(Army Medical University), Sanbin Wang, Yu Li(Shenzhen University Health Science Center), Lin Liu(The University of Melbourne), Jia Liu(Nanjing Medical University), Cheng Zhang(Salk Institute for Biological Studies), Yao Liu(Chongqing University), Le Luo(Central South University), Kun Wu(Kunming Medical University), Lei Gao(Second Military Medical University), Youcheng Wang, Xinxin Wang, Xu Tan(Shantou University), Duanpeng Wang, Dingsong Zhang
Cited by 4
Related Papers
Recent advances in CAR-T cell engineering
|Journal of Hematology & Oncology|2020|403
Genomic and Transcriptomic Characterization of Natural Killer T Cell Lymphoma
|Cancer Cell|2020|234
HDAC6 Is Required for Epidermal Growth Factor-induced β-Catenin Nuclear Localization
|Journal of Biological Chemistry|2008|174
TET2 Function in Hematopoietic Malignancies, Immune Regulation, and DNA Repair
|Frontiers in Oncology|2019|115
Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2
|Nature Chemical Biology|2020|114